×
About 4,015 results

ALLMedicine™ Hyperkalemia Center

Research & Reviews  1,141 results

Hyporeninemic Hypoaldosteronism
https://emedicine.medscape.com/article/242494-overview

Jan 20th, 2022 - Practice Essentials This article reviews some of the pathophysiologic aspects and the clinical picture of, as well as treatment strategies for, hyporeninemic hypoaldosteronism, a condition in which hyperkalemia results from a deficiency of renin a...

The prevalence of predialysis hyperkalemia and associated characteristics among hemodia...
https://doi.org/10.1111/hdi.13006
Hemodialysis International. International Symposium on Ho... Agiro A, Duling I et. al.

Jan 18th, 2022 - Hyperkalemia (HK), defined as serum potassium (K+ ) >5.0 mEq/L, is an independent predictor of mortality in patients on maintenance hemodialysis (HD). This study investigated the annual prevalence of HK and examined patient characteristics potenti...

Adrenal Crisis
http://emedicine.medscape.com/article/116716-overview

Jan 13th, 2022 - Practice Essentials Do not confuse acute adrenal crisis with Addison disease. In 1855, Thomas Addison described a syndrome of long-term adrenal insufficiency that develops over months to years, with weakness, fatigue, anorexia, weight loss, and hy...

A mathematical model of the rat kidney IV: whole-kidney response to hyperkalemia.
https://doi.org/10.1152/ajprenal.00413.2021
American Journal of Physiology. Renal Physiology; Weinstein AM

Jan 11th, 2022 - The renal response to acute hyperkalemia is mediated by increased K secretion within connecting tubule (CNT), flux that is modulated by tubular effects (e.g. aldosterone) in conjunction with increased luminal flow. There is ample evidence that per...

Familial hyperkalemic hypertension: hyperkalemia not hypertension defines dominant KLHL...
https://doi.org/10.1007/s40620-021-01217-5 10.1038/nature10814 10.1146/annurev-physiol-021115-105431 10.1681/ASN.2017060660 10.1016/j.kint.2018.05.001 10.1073/pnas.1421441112 10.1093/ndt/gfz173
Journal of Nephrology; Sambharia M, Gattineni J et. al.

Jan 10th, 2022 - Familial hyperkalemic hypertension: hyperkalemia not hypertension defines dominant KLHL3 disease and may permit earlier recognition and tailored therapy.|2022|Sambharia M,Gattineni J,Noureddine L,Mansilla MA,Thomas CP,|

see more →

Guidelines  1 results

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood...
https://doi.org/10.1016/j.cjca.2016.02.066
The Canadian Journal of Cardiology; Leung AA, Nerenberg K et. al.

Apr 28th, 2016 - Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force provides annually updated, evidence-based recommendations to guide the diagnosis, assessment, prevention, and treatment of hypertension. This year, we present 4 ne...

see more →

Drugs  142 results see all →

Clinicaltrials.gov  51 results

CRRT Timing in Sepsis-associated AKI in ICU
https://clinicaltrials.gov/ct2/show/NCT03175328

Dec 22nd, 2021 - In our study, 460 patients with SAKI at KDIGO 2 from multicenter in China will be recruited. And then the patients will be divided into early group and delayed group randomly. In the early group, CRRT was started immediately after randomization. I...

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
https://clinicaltrials.gov/ct2/show/NCT04676646

Dec 14th, 2021 - REALIZE-K is a Phase 4, multinational, multicenter, double-blind, placebo-controlled, randomized-withdrawal, parallel-group study that includes the following 3 phases: screening, 4-6 week open-label run-in phase where sodium zirconium cyclosilicat...

Occurrence of Dyskalemia With Treatment for Hypertension
https://clinicaltrials.gov/ct2/show/NCT05155436

Dec 13th, 2021 - Hypertension affects an estimated 1.04 billion people in low- and middle-income countries, with an estimated increase in prevalence of 7.7% between 2000 and 2010.1 Hypertension treatment and control may lower the risk of cardiovascular disease and...

Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans
https://clinicaltrials.gov/ct2/show/NCT05145309

Dec 6th, 2021 - This is a double blind, randomized crossover trial comprising two phases: Placebo Phase (microcrystalline cellulose in water) and KMgCit Phase (KMgCit powder in water) to investigate the use of KMgCit in lowering blood pressure and reducing arteri...

Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects
https://clinicaltrials.gov/ct2/show/NCT05136664

Nov 29th, 2021 - In Part A, participants who meet all eligibility criteria will initiate patiromer at an oral dose of 8.4 g (1 packet/day). The dose will be adjusted based on the serum potassium (sK+) levels. After the completion of part A, all the participants wh...

see more →

News  271 results

Fast Five Quiz: Workup for Hyperkalemia
https://www.medscape.com/viewarticle/963569

Dec 9th, 2021 - Hyperkalemia is characterized by serum or plasma potassium levels above the upper limits of normal, typically greater than 5.0-5.5 mEq/L. Although patients with mild hyperkalemia are often asymptomatic, high levels of potassium may cause life-thre...

Fast Five Quiz: Hyperkalemia Signs and Symptoms
https://www.medscape.com/viewarticle/943636

Dec 7th, 2021 - Hyperkalemia refers to an elevation in potassium concentration, usually defined as a serum potassium concentration greater than approximately 5.0-5.5 mEq/L in adults. Prevalence estimates range from 1.5% in the general population, 5.6% in patients...

Fast Five Quiz: Can You Identify and Treat Hyperkalemia?
https://www.medscape.com/viewarticle/849260

Dec 3rd, 2021 - Hyperkalemia — serum potassium greater than approximately 5.0-5.5 mEq/L in adults — is associated with kidney disease, heart failure, a diet high in potassium, and drugs that impair renal potassium excretion. It can also appear in infants or child...

Will the Positive Findings From the SSaSS Trial on Salt Substitution Silence the Salt Skeptics?
https://www.medscape.com/viewarticle/957510

Sep 2nd, 2021 - This transcript has been edited for clarity. John M. Mandrola, MD: Hey everyone, this is John Mandrola from the heart.org | Medscape Cardiology, and I'm delighted to be with Professor Bruce Neal, who is professor of medicine at University of New S...

FDA OKs New Drug for CKD-Related Pruritus
https://www.medpagetoday.com/nephrology/esrd/94182

Aug 24th, 2021 - The FDA approved difelikefalin (Korsuva) on Monday for treating pruritus in chronic kidney disease (CKD) patients, Cara Therapeutics and Vifor Pharma announced. Difelikefalin is a first-in-class kappa opioid receptor (KOR) agonist that targets the...

see more →